GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Short Interest

InflaRx NV (InflaRx NV) Short Interest


View and export this data going back to 2017. Start your Free Trial

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison

For the Biotechnology subindustry, InflaRx NV's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InflaRx NV Short Interest Distribution

For the Biotechnology industry and Healthcare sector, InflaRx NV's Short Interest distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Short Interest falls into.


InflaRx NV (InflaRx NV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Short Interest
Comparable Companies
VXRT INO NKTX THRX ANIX CDXC PRLD AADI PRQR MLEC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
IF0:Germany IF0:Germany
Address
Winzerlaer Strasse 2, Jena, DEU, 07745
Website
https://www.inflarx.de
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.